American Renal Associates Holdings Inc. (NYSE:ARA)’s share price was down 3.3% on Wednesday . The stock traded as low as $21.02 and last traded at $21.47, with a volume of 56,160 shares trading hands. The stock had previously closed at $22.21.

Several equities analysts have recently weighed in on ARA shares. SunTrust Banks Inc. started coverage on American Renal Associates Holdings in a research note on Monday, May 16th. They issued a “buy” rating and a $34.00 price objective on the stock. Zacks Investment Research raised American Renal Associates Holdings from a “hold” rating to a “buy” rating and set a $29.00 price objective on the stock in a research note on Monday, July 18th. Leerink Swann reaffirmed a “buy” rating on shares of American Renal Associates Holdings in a research note on Thursday, August 11th. Barclays PLC reaffirmed a “buy” rating and issued a $31.00 price objective on shares of American Renal Associates Holdings in a research note on Thursday, August 18th. Finally, Bank of America Corp. reiterated a “buy” rating and set a $35.00 target price on shares of American Renal Associates Holdings in a report on Monday, August 22nd. Two analysts have rated the stock with a hold rating and five have issued a buy rating to the stock. American Renal Associates Holdings has a consensus rating of “Buy” and an average target price of $31.17.

The company’s market cap is $655.33 million. The company’s 50 day moving average is $23.55 and its 200 day moving average is $26.03.

American Renal Associates Holdings (NYSE:ARA) last issued its quarterly earnings data on Tuesday, August 9th. The company reported ($0.75) earnings per share (EPS) for the quarter. The firm earned $185.60 million during the quarter, compared to the consensus estimate of $161.50 million. Analysts predict that American Renal Associates Holdings Inc. will post $0.96 earnings per share for the current year.

American Renal Associates Holdings, Inc is a dialysis services provider in the United States. The Company focuses on joint venture partnerships with physicians. The Company’s segment is the ownership and operation of dialysis clinics. It provides patient care and clinical outcomes to patients suffering from the advanced stage of chronic kidney disease, known as end stage renal disease (ESRD).

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.